Alex Odoom, Eugene M. Obeng, Christian Dzuvor
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Receptor recognition mechanisms of coronaviruses: a decade of structural studies
10.1128/jvi.02615-14 · 2015
An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants
10.1126/sciadv.abf1738 · 2021
Engineered DPP4 decoy confers broad-spectrum inhibition of MERS-CoV infection
10.1016/j.celbio.2025.100018 · 2025
Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2
10.1038/s41467-021-24013-y · 2021
De novo design of picomolar SARS-CoV-2 miniprotein inhibitors
10.1126/science.abd9909 · 2020
Beyond MERS: merbecovirus receptor plasticity calls for emergence preparedness
10.1016/j.chom.2025.03.013 · 2025
Multivalent IgM scaffold enhances the therapeutic potential of variant-agnostic ACE2 decoys against SARS-CoV-2
10.1080/19420862.2023.2212415 · 2023
Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice
10.1126/scitranslmed.abn1252 · 2022
The ACE2 decoy receptor can overcome immune escape by rapid mutating SARS-CoV-2 variants and reduce cytokine induction and clot formation
10.1186/s12929-025-01156-4 · 2025
Confidence 96%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
Computational design and engineering of self-assembling multivalent microproteins with therapeutic potential against SARS-CoV-2
10.1186/s12951-024-02329-3 · 2024
An IgM-like inhalable ACE2 fusion protein broadly neutralizes SARS-CoV-2 variants
10.1038/s41467-023-40933-3 · 2023
Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities
2022
Engineered ACE2 decoy in dry powder form for inhalation: a novel therapy for SARS-CoV-2 variants
10.1016/j.omtm.2025.101459 · 2025
Vectored immunoprophylaxis and treatment of SARS-CoV-2 infection in a preclinical model
10.1073/pnas.2303509120 · 2023
Quantitative characterisation of extracellular vesicles designed to decoy or compete with SARS-CoV-2 reveals differential mode of action across variants of concern and highlights the diversity of Omicron
10.1186/s12964-025-02223-x · 2025
Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines
10.1073/pnas.2014352117 · 2020
Biomaterials for intranasal and inhaled vaccine delivery
10.1038/s44222-022-00012-6 · 2023
An inhaled ACE2 decoy confers protection against SARS-CoV-2 infection in preclinical models
10.1126/scitranslmed.adi2623 · 2023
No additional external references are available.
